Use of the GTPγS ([ 35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors

British Journal of Pharmacology

Volumn 161, Issue 6, 2010, Pages 1238-1249

  Strange, Philip G ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Agonist; Antagonist; Drug screening; Efficacy; Functional assay; GTP S binding assay; Inverse agonist

Indexed keywords

ADENOSINE A1 RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; CANNABINOID 1 RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; G PROTEIN COUPLED RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE DIPHOSPHATE; MAGNESIUM ION; MUSCARINIC RECEPTOR; SAPONIN; SEROTONIN 1A AGONIST; SEROTONIN 1B RECEPTOR; SODIUM ION;

BINDING ASSAY; CONCENTRATION RESPONSE; DRUG PROTEIN BINDING; EQUILIBRIUM CONSTANT; HIGH THROUGHPUT SCREENING; HUMAN; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; DRUG INVERSE AGONISM; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; LIGANDS; RADIOLIGAND ASSAY; RECEPTORS, G-PROTEIN-COUPLED; SULFUR RADIOISOTOPES;

EID: 78049359776     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00963.x     Document Type: Review

References (74)

1. Akam EC, Challiss RA, Nahorski SR (2001). G(q/11) and G(i/o) activation profiles in CHO cells expressing human muscarinic acetylcholine receptors: dependence on agonist as well as receptor-subtype. Br J Pharmacol 132: 950-958.
2. Alt A, McFadyen IJ, Fan CD, Woods JH, Traynor JR (2001). Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein. J Pharmacol Exp Ther 298: 116-121.
3. Asano T, Pedersen SE, Scott CW, Ross EM (1984). Reconstitution of catecholamine-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to the stimulatory GTP-binding protein of adenylate cyclase. Biochemistry 23: 5460-5467.
4. Bidlack JM, Jadrovski I (2000). Pharmacological profiles of kappa opioids. Correlation between [35S]GTP gamma S binding and cyclic AMP production. Ann NY Acad Sci 909: 264.
5. Birdsall NJ, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, Sugimoto M (1999). Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mol Pharmacol 55: 778-786.
6. Bokoch GM, Katada T, Northup JK, Ui M, Gilman AG (1984). Purification and properties of the inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. J Biol Chem 259: 3560-3567.
7. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier M et al. (1997). A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem 272: 22330-22339.
8. Breivogel CS, Selley DE, Childers SR (1998). Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. J Biol Chem 273: 16865-16873.
9. Breivogel CS, Walker JM, Huang SM, Roy MB, Childers SR (2004). Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. Neuropharmacology 47: 81-91.
10. Brinkerhoff CJ, Traynor JR, Linderman JJ (2008). Collision coupling, crosstalk, and compartmentalization in G-protein coupled receptor systems: can a single model explain disparate results? J Theor Biol 255: 278-286.
11. Bunemann M, Frank M, Lohse MJ (2003). Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. Proc Natl Acad Sci USA 100: 16077-16082.
12. Clark MJ, Furman CA, Gilson TD, Traynor JR (2006). Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther 317: 858-864.
13. Cohen FR, Lazareno S, Birdsall NJ (1996). The effects of saponin on the binding and functional properties of the human adenosine A1 receptor. Br J Pharmacol 117: 1521-1529.
14. Cordeaux Y, Nickolls SA, Flood LA, Graber SG, Strange PG (2001). Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype. J Biol Chem 276: 28667-28675.
15. Costa T, Ogino Y, Munson PJ, Onaran HO, Rodbard D (1992). Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol Pharmacol 41: 549-560.
16. Cussac D, Newman-Tancredi A, Duqueyroix D, Pasteau V, Millan MJ (2002). Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol 62: 578-589.
17. DeLapp NW (2004). The antibody-capture [(35)S]GTPgammaS scintillation proximity assay: a powerful emerging technique for analysis of GPCR pharmacology. Trends Pharmacol Sci 25: 400-401.
18. DeLapp NW, McKinzie JH, Sawyer BD, Vandergriff A, Falcone J, McClure D et al. (1999). Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. J Pharmacol Exp Ther 289: 946-955.
19. Ehlert FJ, Griffin MT, Sawyer GW, Bailon R (1999). A simple method for estimation of agonist activity at receptor subtypes: comparison of native and cloned M3 muscarinic receptors in guinea pig ileum and transfected cells. J Pharmacol Exp Ther 289: 981-992.
20. Frank M, Thumer L, Lohse MJ, Bunemann M (2005). G Protein activation without subunit dissociation depends on a G{alpha}(i)-specific region. J Biol Chem 280: 24584-24590.
21. Gardner B, Strange PG (1998). Agonist action at D2(long) dopamine receptors: ligand binding and functional assays. Br J Pharmacol 124: 978-984.
22. Gardner B, Hall DA, Strange PG (1996). Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells. Br J Pharmacol 118: 1544-1550.
23. Gazi L, Nickolls SA, Strange PG (2003). Functional coupling of the human dopamine D2 receptor with G alpha i1, G alpha i2, G alpha i3 and G alpha o G proteins: evidence for agonist regulation of G protein selectivity. Br J Pharmacol 138: 775-786.
24. Gettys TW, Sheriff-Carter K, Moomaw J, Taylor IL, Raymond JR (1994). Characterization and use of crude alpha-subunit preparations for quantitative immunoblotting of G proteins. Anal Biochem 220: 82-91.
25. Harrison C, Traynor JR (2003). The [35S]GTPgammaS binding assay: approaches and applications in pharmacology. Life Sci 74: 489-508.
26. Haworth B, Lin H, Fidock M, Dorr P, Strange PG (2007). Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem Pharmacol 74: 891-897.
27. Heise CE, Pahuja A, Hudson SC, Mistry MS, Putnam AL, Gross MM et al. (2005). Pharmacological characterization of CXC chemokine receptor 3 ligands and a small molecule antagonist. J Pharmacol Exp Ther 313: 1263-1271.
28. Heusler P, Newman-Tancredi A, Castro-Fernandez A, Cussac D (2007). Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology 52: 1106-1113.
29. Higashijima T, Ferguson KM, Sternweis PC, Smigel MD, Gilman AG (1987). Effects of Mg2+ and the beta gamma-subunit complex on the interactions of guanine nucleotides with G proteins. J Biol Chem 262: 762-766.
30. Hilf G, Gierschik P, Jakobs KH (1989). Muscarinic acetylcholine receptor-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes. Eur J Biochem 186: 725-731.
31. Horswill JG, Bali U, Shaaban S, Keily JF, Jeevaratnam P, Babbs AJ et al. (2007). PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 152: 805-814.
32. Johnson EN, Shi X, Cassaday J, Ferrer M, Strulovici B, Kunapuli P (2008). A 1, 536-well [(35)S]GTPgammaS scintillation proximity binding assay for ultra-high-throughput screening of an orphan galphai-coupled GPCR. Assay Drug Dev Technol 6: 327-337.
33. Kara E, Strange PG (2010). Use of the [35S]GTPgS binding assay to determine ligand efficacy at G protein-coupled receptors. In: Poyner D, Wheatley M (eds). G Protein-Coupled Receptors: Essential Methods. Wiley-VCH: Weinheim, Germany, pp. 53-68.
34. Kenakin T (2004). Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol Pharmacol 65: 2-11.
35. Kenakin T, Jenkinson S, Watson C (2006). Determining the potency and molecular mechanism of action of insurmountable antagonists. J Pharmacol Exp Ther 319: 710-723.
36. Kitazawa T, Asakawa K, Nakamura T, Teraoka H, Unno T, Komori SI et al. (2009). M3 muscarinic receptors mediate positive inotropic responses in mouse atria: a study with muscarinic receptor knockout mice. J Pharmacol Exp Ther 330: 487-493.
37. Koval A, Kopein D, Purvanov V, Katanaev VL (2010). Europium-labeled GTP as a general nonradioactive substitute for [(35)S]GTPgammaS in high-throughput G protein studies. Anal Biochem 397: 202-20.
38. Kurose H, Katada T, Haga T, Haga K, Ichiyama A, Ui M (1986). Functional interaction of purified muscarinic receptors with purified inhibitory guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles. J Biol Chem 261: 6423-6428.
39. Labrecque J, Anastassov V, Lau G, Darkes M, Mosi R, Fricker SP (2005). The development of an europium-GTP assay to quantitate chemokine antagonist interactions for CXCR4 and CCR5. Assay Drug Dev Technol 3: 637-648.
40. Labrecque J, Wong RS, Fricker SP (2009). A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery. Methods Mol Biol 552: 153-169.
41. Lane JR, Powney B, Wise A, Rees S, Milligan G (2007). Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist/inverse agonist for Gi1, Gi2, and Gi3. Mol Pharmacol 71: 1349-1359.
42. Lazareno S, Birdsall NJ (1993). Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies. Br J Pharmacol 109: 1120-1127.
43. Lazareno S, Farries T, Birdsall NJ (1993). Pharmacological characterization of guanine nucleotide exchange reactions in membranes from CHO cells stably transfected with human muscarinic receptors m1-m4. Life Sci 52: 449-456.
44. Leopoldo M, Lacivita E, Colabufo NA, Contino M, Berardi F, Perrone R (2005). First structure-activity relationship study on dopamine D3 receptor agents with N-[4-(4-arylpiperazin-1-yl)butyl]arylcarboxamide structure. J Med Chem 48: 7919-7922.
45. Lin H, Saisch SG, Strange PG (2006). Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor. Br J Pharmacol 149: 291-299.
46. Lorenzen A, Fuss M, Vogt H, Schwabe U (1993). Measurement of guanine nucleotide-binding protein activation by A1 adenosine receptor agonists in bovine brain membranes: stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding. Mol Pharmacol 44: 115-123.
47. Martel JC, Ormiere AM, Leduc N, Assie MB, Cussac D, Newman-Tancredi A (2007). Native rat hippocampal 5-HT1A receptors show constitutive activity. Mol Pharmacol 71: 638-643.
48. McLoughlin DJ, Strange PG (2000). Mechanisms of agonism and inverse agonism at serotonin 5-HT1A receptors. J Neurochem 74: 347-357.
49. Milligan G (2003). Principles: extending the utility of [35S]GTP gamma S binding assays. Trends Pharmacol Sci 24: 87-90.
50. Mueller A, Mahmoud NG, Goedecke MC, McKeating JA, Strange PG (2002). Pharmacological characterization of the chemokine receptor, CCR5. Br J Pharmacol 135: 1033-1043.
51. Newman-Tancredi A, Chaput C, Touzard M, Millan MJ (2000). [(35)S]-GTPgammaS autoradiography reveals alpha(2) adrenoceptor-mediated G-protein activation in amygdala and lateral septum. Neuropharmacology 39: 1111-1113.
52. Newman-Tancredi A, Rivet JM, Cussac D, Touzard M, Chaput C, Marini L et al. (2003). Comparison of hippocampal G protein activation by 5-HT(1A) receptor agonists and the atypical antipsychotics clozapine and S16924. Naunyn Schmiedebergs Arch Pharmacol 368: 188-199.
53. Nickolls SA, Strange PG (2003). Interaction of the D2short dopamine receptor with G proteins: analysis of receptor/G protein selectivity. Biochem Pharmacol 65: 1139-1150.
54. Otero AD (1990). Transphosphorylation and G protein activation. Biochem Pharmacol 39: 1399-1404.
55. Pauwels PJ, Tardif S, Palmier C, Wurch T, Colpaert FC (1997). How efficacious are 5-HT1B/D receptor ligands: an answer from GTP gamma S binding studies with stably transfected C6-glial cell lines. Neuropharmacology 36: 499-512.
56. Pauwels PJ, Wurch T, Palmier C, Colpaert FC (1998). Pharmacological analysis of G-protein activation mediated by guinea-pig recombinant 5-HT1B receptors in C6-glial cells: similarities with the human 5-HT1B receptor. Br J Pharmacol 123: 51-62.
57. Payne SL, Johansson AM, Strange PG (2002). Mechanisms of ligand binding and efficacy at the human D2(short) dopamine receptor. J Neurochem 82: 1106-1117.
58. Quirk K, Roberts DJ, Strange PG (2007). Mechanisms of G protein activation via the D2 dopamine receptor: evidence for persistent receptor/G protein interaction after agonist stimulation. Br J Pharmacol 151: 144-152.
59. Raymond JR, Olsen CL, Gettys TW (1993). Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha. Biochemistry 32: 11064-11073.
60. Roberts DJ, Strange PG (2005). Mechanisms of inverse agonist action at D2 dopamine receptors. Br J Pharmacol 145: 34-42.
61. Roberts DJ, Lin H, Strange PG (2004). Mechanisms of agonist action at D2 dopamine receptors. Mol Pharmacol 66: 1573-1579.
62. Rozwandowicz-Jansen A, Laurila J, Martikkala E, Frang H, Hemmila I, Scheinin M et al. (2010). Homogeneous GTP binding assay employing QRET technology. J Biomol Screen 15: 261-267.
63. Salah-Uddin H, Thomas DR, Davies CH, Hagan JJ, Wood MD, Watson JM et al. (2008). Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue. J Pharmacol Exp Ther 325: 869-874.
64. Selley DE, Sim LJ, Xiao R, Liu Q, Childers SR (1997). mu-Opioid receptor-stimulated guanosine-5'-O-(gamma-thio)-triphosphate binding in rat thalamus and cultured cell lines: signal transduction mechanisms underlying agonist efficacy. Mol Pharmacol 51: 87-96.
65. Selley DE, Liu Q, Childers SR (1998). Signal transduction correlates of mu opioid agonist intrinsic efficacy: receptor-stimulated [35S]GTP gamma S binding in mMOR-CHO cells and rat thalamus. J Pharmacol Exp Ther 285: 496-505.
66. Selley DE, Cao CC, Liu Q, Childers SR (2000). Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus. Br J Pharmacol 130: 987-996.
67. Sim LJ, Selley DE, Dworkin SI, Childers SR (1996). Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16: 2684-2692.
68. Sternweis PC, Robishaw JD (1984). Isolation of two proteins with high affinity for guanine nucleotides from membranes of bovine brain. J Biol Chem 259: 13806-13813.
69. Strange PG (2007). Mechanisms underlying agonist efficacy. Biochem Soc Trans 35 (Pt 4): 733-736.
70. Strange PG (2008). Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. Br J Pharmacol 153: 1353-1363.
71. Tian WN, Duzic E, Lanier SM, Deth RC (1994). Determinants of alpha 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state. Mol Pharmacol 45: 524-531.
72. Wieland T, Liedel K, Kaldenberg-Stasch S, Meyer zu Heringdorf D, Schmidt M, Jakobs KH (1995). Analysis of receptor-G protein interactions in permeabilized cells. Naunyn Schmiedebergs Arch Pharmacol 351: 329-336.
73. Wise A, Sheehan M, Rees S, Lee M, Milligan G (1999). Comparative analysis of the efficacy of A1 adenosine receptor activation of Gi/o alpha G proteins following coexpression of receptor and G protein and expression of A1 adenosine receptor-Gi/o alpha fusion proteins. Biochemistry 38: 2272-2278.
74. Wood MD, Scott C, Clarke K, Westaway J, Davies CH, Reavill C et al. (2006). Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. Eur J Pharmacol 546: 88-94.